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Abstract: Stroke is a leading cause of death, disability and dementia worldwide. Despite 
extensive pre-clinical investigation, few therapeutic treatment options are available to 
patients, meaning that death, severe disability and the requirement for long-term 
rehabilitation are common outcomes. Cell loss and tissue injury following stroke occurs 
through a number of diverse secondary injury pathways, whose delayed nature provides an 
opportunity for pharmacological intervention. Amongst these secondary injury factors, 
increased blood-brain barrier permeability and cerebral oedema are well-documented 
complications of cerebral ischaemia, whose severity has been shown to be associated with 
final outcome. Whilst the mechanisms of increased blood-brain barrier permeability and 
cerebral oedema are largely unknown, recent evidence suggests that the neuropeptide 
substance P (SP) plays a central role. The aim of this review is to examine the role of SP in 
ischaemic stroke and report on the potential utility of NK1 tachykinin receptor antagonists 
as therapeutic agents. 
Keywords: substance P; neuropeptides; neurogenic inflammation; cerebral oedema; 
stroke; tachykinin; blood-brain barrier; cerebral ischaemia 
 
1. Introduction 
Stroke is a major health problem in western nations and is a leading cause of morbidity, mortality 
and dementia. Specifically, each year a staggering 15 million people worldwide will suffer a stroke, of 
which 5 million will die and 5 million will be left permanently disabled. The social and economic costs 
of stroke are consequently enormous. In Australia alone, the cost of hospitalisation, treatment and 
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rehabilitation of stroke patients is estimated at $1.2–1.7 billion per year [1]. At present, thrombolysis 
with tissue plasminogen activator within 4.5 h of symptom onset is the only approved stroke  
therapy [2] but is only received by some 5%–15% of stroke patients. As such, novel therapies that can 
limit or reverse ischaemic injury are urgently required.  
2. Secondary Injury 
Ischaemic stroke is the result of an obstruction to the brain vasculature, thereby restricting the 
supply of blood that contains vital oxygen and substrates for neurons. If blood flow is not rapidly 
restored, death of cells may result with associated long-term functional deficits [3]. Whilst restoration 
of blood flow is seen as a priority in both reducing the degree of tissue injury and preserving 
neurological function, it is now accepted that secondary injury mechanisms continue to evolve after 
stroke and also contribute to the size of the infarct [4]. The infarction can be considered as being made 
up of two components, the infarct core and the surrounding penumbral tissue [5]. The infarct core is 
widely considered to be irreversibly damaged during ischaemic stroke with cell death occurring 
rapidly within this region. In the penumbral tissue, however, there is less restricted blood flow and 
therefore an opportunity for neuronal tissue to survive the insult. Nonetheless, cell death may continue 
to occur here as a result of secondary biochemical and physiological mechanisms that manifest over 
the hours to days following stroke [4,5]. There is a diverse array of secondary injury processes that 
contribute to injury and cell loss, including excitotoxicity, oxidative stress, inflammation, apoptosis, 
increased vascular permeability and cerebral oedema, amongst others (Figure 1) [6]. Given the delayed 
nature of secondary injury an opportunity therefore exists for pharmacological intervention to limit 
tissue damage and cell death. Accordingly, much research has focused on the characterization of 
secondary injury pathways so as to develop therapies that reduce or ameliorate such pathways. 
Figure 1. Secondary injury pathways that occur following ischaemic stroke. 
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2.1. Blood-Brain Barrier (BBB) 
The blood-brain barrier (BBB) is a highly selective barrier that serves to regulate the entry of  
blood-borne substances, some of which may damage the fragile brain extracellular environment [7]. It 
is made up of a complex cellular system of cells of the cerebral capillaries and post-capillary venules 
resting on the basal lamina [6]. The BBB facilitates a constant supply of nutrients, preserves ion 
homeostasis within the brain microenvironment, and protects against noxious chemicals, variations in 
blood composition and the breakdown of concentration gradients. The gate function of the BBB is 
provided by the tight and adherin junctions, a complex network of transmembrane and cytosolic 
proteins [7]. However, in conditions of ischaemia, there is a loss of BBB integrity such that alterations 
in vascular permeability and basal lamina structure occur [8,9]. Deprivation of blood flow to 
downstream microvasculature activates a cascade of events, including activation of coagulation 
factors, disruption of the extracellular matrix and increased capillary permeability [10,11]. Endothelial 
dysfunction occurs and leads to early permeability increases that cause extravasation of plasma 
components and oedema formation [7,10]. In addition, loss of basal lamina integrity causes red blood 
cell leakage and the development of haemorrhagic transformation; inflammatory cells, cytokines, 
proteases and free radicals have all been linked to such damage [6,12].  
The exact mechanism by which ischaemia disrupts the BBB is debatable; however acute 
hypertension, hyperosmolar solutions, inflammation and more recently the matrix metalloproteinase 
family, have all been implicated [7]. The exact time course of BBB disruption following stroke also 
remains a contentious issue, although experimental studies have demonstrated a biphasic opening of 
the BBB [9,11,13], with early changes in BBB permeability observed at 2–3 h after the onset of 
vascular occlusion, while a second and delayed opening is typically observed at 24–48 h, the latter 
being associated with more intense blood vessel damage [11].  
2.2. Cerebral Oedema 
Of all the secondary injury factors, cerebral oedema, defined as an abnormal accumulation of fluid 
within the brain, is of particular concern given its association with increased mortality and morbidity 
after stroke [14,15]. Klatzo and colleagues [16] were the first to classify oedema into two broad 
categories based upon the integrity of the BBB: vasogenic and cytotoxic oedema [12]. The type and 
severity of cerebral oedema may be influenced by the duration and severity of ischaemia and 
reperfusion status, amongst other factors, and may also differ between the core and the penumbra of 
the stroke lesion. 
Cytotoxic oedema is an intracellular oedema that occurs secondary to cellular injury and represents 
a shift of water from the extracellular compartment to the intracellular compartment, accompanied by 
shrinkage of the extracellular space [6]. It occurs independently of alterations in the BBB and appears 
to be more prominent in the grey matter [15]. Failure of the Na+/K+ ATPase in regions of energy 
failure and subsequent loss of ion homeostasis, leading to influx of water into cells, is central to the 
development of cytotoxic oedema [11,17,18]. Conversely, vasogenic oedema is more prevalent in the 
white matter [15] and involves the escape of proteins from the vasculature in the setting of BBB 
disruption and injury to cerebral blood vessels [11]. Protein accumulation in the brain extracellular 
space causes an osmotic increase at the site of injury and the subsequent movement of water down its 
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osmotic gradient [11]. There is a strong correlation between extravasation of proteins into the 
extracellular space and the development of vasogenic oedema [9,13]. Vasogenic oedema is of 
particular importance not only because it increases brain volume, but also because in the setting of 
vascular recanalisation it increases risk of haemorrhagic transformation from damaged blood vessels 
and excess fluid accumulation [10]. 
Cerebral oedema is a major cause of clinical deterioration within the first 24 h, the leading cause of 
death within the first week, and is a predictor of poor outcome following stroke [14]. Clinical studies 
report that it is maximal between 1 and 3 days following stroke [15], whilst experimental studies report 
its presence as early as 15 min after the onset of vascular occlusion [19]. Cerebral oedema can lead to 
an increase in intracranial pressure (ICP), the sequelae of which include reduced cerebral blood flow, 
further ischaemia and infarct extension, deformation and herniation of the brain tissue, and in severe 
cases, death [10,14,15,20,21]. With the mortality of malignant cerebral oedema approaching  
80% [15,22], the importance of reducing cerebral oedema and the resultant rise in ICP is now widely 
recognised as a major clinical management target. Conventional treatments seek to reduce brain 
swelling and ICP though administration of hyperosmotic agents and barbiturates, induction of 
hyperventilation or hypothermia, and surgical interventions such as cerebrospinal fluid (CSF) 
drainage, or in severe cases, decompressive craniectomy [14]. With respect to patient morbidity and 
mortality such treatment regimes have proven somewhat ineffective, mainly because they do not 
address the specific mechanisms that are associated with the genesis of oedema in cerebral ischaemia. 
Recent studies have identified substance P (SP) release as a feature of acute injury to the brain and 
have delineated a critical role for SP in increased BBB permeability and the development of  
vasogenic oedema. 
3. Substance P 
SP is an 11 amino acid peptide that is a member of the tachykinin family, so named for their  
fast-acting properties [23], which also includes neurokinin A (NKA), neurokinin B (NKB), 
neuropeptide K (NPK) and neuropeptide γ (NPγ), amongst others. It was first isolated by von Euler 
and Gaddum in the 1930’s as a crude extract from equine brain and gut that demonstrated potent 
hypotensive and smooth muscle contractile properties. It was subsequently named substance “P” for 
the powder from which it was extracted [24]. Initially, SP was identified in high concentrations in the 
dorsal root ganglia of the spinal cord, which drove speculation that it functioned as a neuronal sensory 
transmitter in the transmission of pain signals. It is now known that SP is released from both central 
and peripheral endings of primary afferent neurons where it functions as a neurotransmitter [23,25]. 
3.1. Synthesis 
SP, along with other tachykinins, is produced from the preprotachykinin (PPT) A and B genes. 
Alternate splicing of the PPTA gene yields the β- and γ-transcripts giving rise to SP, NKA, NPK and 
NKγ, whereas the α- and δ- transcripts produce SP only. The PPTB gene only encodes for NKB. SP 
synthesis occurs at the cell body ribosomes where it is then packaged into vesicles and axonally 
transported to the terminal endings for final enzymatic processing [26]. Precursor proteins are stored in 
secretory granules along with processing enzymes for post-translational modifications and release of 
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the active peptide [27,28]. The biologically active peptide is then stored in large, dense vesicles ready 
for release. Under normal conditions substantial amounts of SP are synthesised and stored within 
neurons [26]. However, activation or damage of these neurons results in the rapid release of SP and 
other neuropeptides [27].  
3.2. Localisation 
SP is widely distributed throughout the central and peripheral nervous systems, with α-PPTA 
transcripts more abundant within the brain and β-PPTA transcripts more abundant in peripheral tissues. 
The main feature of SP immunoreactivity is co-localisation with other classical transmitters such as 
serotonin and glutamate, and other neuropeptides such as calcitonin gene-related peptide (CGRP) and 
NKA [26,29]. Specifically, in the brain SP immunoreactivity has been demonstrated in the 
rhinencephalon, telencephalon, basal ganglia, hippocampus, amygdala, septal areas, diencephalon, 
hypothalamus, mesencephalon, metencephalon, pons, myelencephalon and spinal cord. In peripheral 
tissues, SP and other sensory neuropeptides are distributed throughout the gut, respiratory system, 
urinary system, immune system, blood and blood vessels [30]. 
SP is localised in capsaicin sensitive neurons and is released from central and peripheral endings of 
primary afferent neurons in response to various noxious stimuli [27,31]. Capsaicin itself causes the 
release of neuropeptides from these sensory nerve fibres to the point of depletion, hence being referred 
to as “capsaicin-sensitive” neurons. However, chronic exposure or high concentrations of capsaicin 
leads to permanent depletion [32], thereby blocking the effects of neuropeptides in the genesis of 
neurogenic inflammation and resultant oedema. Accordingly, acute and chronic capsaicin treatment is 
a useful tool to study the effects of neuropeptides in various physiological and pathological settings. 
3.3. Metabolism 
Once released, SP may be cleared and inactivated by many different proteolytic enzymes including 
neutral endopeptidase (NEP) [33,34], angiotensin-converting enzyme (ACE) [33,35,36], SP-degrading 
enzyme [33,37], post-proline endopeptidase [33,38], cathepsin-D [39], cathepsin-E [40],  
SP-hydrolysing enzyme, aminopeptidase P and dipeptidyl aminopeptidase IV [33]. All of these 
enzymes have the capacity to degrade SP in vitro, however it is likely that ACE and NEP are primarily 
involved in the cleavage of SP in vivo due to their cellular location [27]. Both of these enzymes 
catalyse the degradation of the hydrolytic bonds of SP, rendering it inactive without the carboxyl 
terminus required to bind to its receptor [26]. Specifically, NEP has been shown to degrade SP within 
the brain [41], spinal cord [42] and peripheral tissues [27] whereas ACE has been shown to degrade SP 
in plasma, CSF and brain, in particular the substania nigra [43]. 
3.4. Receptors 
The biological actions of SP are mediated through its binding at tachykinin NK receptors which is a 
member of the rhodopsin family of 7-transmembrane G-protein coupled receptors [44]. Currently,  
3 mammalian tachykinin receptors have been identified, the NK1, NK2 and NK3 receptors [45]. The 
tachykinins themselves share some structural homology, a carboxyl terminal sequence that reflects 
their common biological action. Given this, some cross-reactivity amongst tachykinin receptors  
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exists [46] with each of the tachykinins acting on all receptor types, however with varying affinities 
depending upon receptor availability and neuropeptide concentration. Under normal conditions SP has 
a high affinity for the NK1 receptor, NKA for the NK2 receptor and NKB for the NK3  
receptor [47,48]. With respect to the NK1 receptor, it is a 403 amino acid residue protein that is highly 
conserved with only discrete variations amongst species. An NK1 autoreceptor has also been 
characterised purported to be involved in the regulation of SP release [49–52]. NK1 receptors are 
found in their highest levels in the caudate putamen and superior colliculus, however they are also 
found in low to moderate levels in the inferior colliculus, olfactory bulb, hypothalamus, cerebral 
cortex, septum, striatum, mesencephalon and dorsal horn of the spinal cord [53].  
Tachykinins are released in response to Ca2+-dependent depolarisation of neurons, induced by a 
variety of stimuli including electrical stimulation, pH changes and ligand binding to their receptors, 
including capsaicin [28,30]. Once released, SP may have direct post-synaptic actions as a 
neurotransmitter, modulatory function at post-synaptic sites or other functions on non-neuronal  
targets [28]. Transduction of the SP signal occurs through the action of G proteins associated with the 
intracellular domain of the NK1 receptor. The stimulation of G proteins produces an elevation in 
cAMP as a secondary messenger, which through a cascade of events leads to the regulation of ion 
channels, enzyme activity, and changes in gene expression. Although normally confined to the cell 
membrane, the NK1-SP complex is rapidly internalised following SP binding. SP is then removed by 
endosomal acidification and targeted by the lysosomes for degradation, whilst the NK1 receptor is 
recycled to the cell membrane [28]. 
3.5. Functions 
Tachykinins are involved in a diverse array of distinct biological processes such as plasma protein 
extravasation, vasodilation, smooth muscle contraction and relaxation, airway contraction, 
transmission of nociceptive responses, salivary secretion, inflammation as well as higher functions 
including memory formation and reinforcement [47,54]. In terms of pathophysiology, SP has been 
implicated in asthma, inflammatory bowel disease, pain, psoriasis, anxiety, migraine, emesis and 
movement disorders as well as neurological and psychiatric disorders such as psychosis, stroke, 
migraine and pain. Increased SP levels have also been associated with painful conditions such as 
peripheral neuropathy and osteoarthritis. Intracerebroventricular injection of SP in rats results in a 
diverse array of effects including increased blood pressure and heart rate, increased hindlimb rearing 
behaviour, scratching, skin biting and grooming. Injection of SP into the lateral septum induces clear 
aversive behaviour including freezing and jumping followed by darting behaviour in the elevated plus 
maze [55]. In guinea pigs, SP release in the basolateral amygdala elicits distress vocalisations, which 
can be inhibited by the NK1 tachykinin receptors antagonist L760 735 [56]. Post-synaptic dorsal 
column neurons do not the express NK1 tachykinin receptor under control conditions, however in 
visceral inflammation, de novo expression of the NK1 tachykinin receptor occurs, thereby allowing the 
activation of such neurons by SP [57]. 
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3.6. Trigeminovascular System 
Cerebral blood vessels are highly innervated with a combination of sympathetic, parasympathetic 
and trigeminal somatic nerve fibres, all of which play important roles in cerebrovascular  
regulation [58]. The trigeminal component of this innervation is commonly referred to as the 
trigeminovascular system, which has been shown to be involved in the transmission of pain sensation. 
The perivascular endings of these trigeminovascular fibres contain SP [59], CGRP [60,61], NKA, 
nitric oxide [62] and amylin [63]. 
4. Neurogenic Inflammation  
The concept of neurogenic inflammation was first documented by Bayliss in 1901 [64], who 
reported vasodilation of the lower limbs in response to dorsal root ganglia stimulation. The definition 
of neurogenic inflammation has now evolved to encompass a painful local inflammatory response 
characterised by vasodilation, increased vascular permeability, mast cell degranulation and the release 
of neuropeptides including SP and CGRP [30,65]. There are also tissue specific responses including 
smooth muscle contraction/relaxation in the bladder and ionotropic/chronotropic effects on the heart 
and bronchoconstriction in the airways, amongst others [47,66]. Neurogenic inflammation has been 
demonstrated in tissue receiving trigeminal innervation such as oral, nasal, facial and ocular tissue, and 
may be stimulated by many agents including prostanoids, leukotrienes, histamine and serotonin, in 
addition to changes in the extracellular environment such as decreased pH, increased osmolarity, heat, 
inflammatory conditions and tissue injury [27,67].  
The changes in blood vessel size and permeability that occur with neurogenic inflammation lead to 
oedema formation within the tissue [9,13]. Perhaps the most important factor in this response is SP, 
having been identified as the most potent initiator of neurogenic inflammation [25,68]. However, it has 
not been established that SP is the sole peptide with the direct/indirect ability to cause vasodilation and 
plasma extravasation [30]. Neurogenic inflammation leads to increases in both PPT mRNA [27] and 
NK1 receptor mRNA [69]. Oedema and plasma extravasation in response to SP are also associated 
with the release of CGRP, release of histamine and serotonin from mast cells and the release of 
prostanoids and nitric oxide (NO) [47,66]. Some of the effects of SP are related to the ability of the 
peptide to activate neutrophils and thereby produce hydrogen peroxide, superoxide anion and NO. The 
pro-inflammatory effects of tachykinins are also related to activation of nuclear transcription factors 
such as nuclear factor κB [54,70] that increases cytokine levels [70,71]. 
4.1. Neurogenic Inflammation in the Peripheral Nervous System 
The release of neuropeptides, and in particular SP, has long been known to initiate neurogenic 
inflammation in peripheral tissues such as the skin and trachea [30,47]. For example, arterial 
administration of SP leads to vasodilation and plasma extravasation. Alves and colleagues found that 
SP, NKA or NKB injection increase in rat paw oedema, as indicated by increased paw volume [72], 
and that other NK1, NK2 and NK3 receptor agonists similarly increase paw oedema. Consistent with 
this, NK1, NK2 and NK3 tachykinin receptor antagonists inhibit oedema caused by SP, NKA and 
NKB, respectively, in a dose dependent manner. Such findings confirm that SP, NKA and NKB  
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play a role in the control of plasma extravasation and oedema formation and it is likely that all three 
receptor subtypes account for the pro-inflammatory response observed [72]. However, studies in 
knockout mice have shown that loss of the NK1 tachykinin receptor results in decreased plasma 
extravasation within peripheral tissues. In addition, there was a loss of the chemoattractant influence of 
SP, blunted noxious chemical signalling, decreased anxiety and blunting of response to danger. Studies 
examining neurogenic inflammation in the skin of NK1 tachykinin receptor knockout mice have also 
shown that they are unable to produce oedema, even though application of SP produces plasma 
extravasation and oedema formation in a dose-dependent manner in wild-type mice [31]. In guinea pig 
skin, SP causes oedema formation and white blood cell accumulation, both of which are inhibited by 
co-injection of the NK1 tachykinin receptor antagonist RP 67580 [54]. In mouse ear skin, SP, NKA 
and NKB all cause oedema formation. While all of these neuropeptides play a role in controlling 
plasma extravasation and oedema formation, SP is the major contributor. NK1 tachykinin receptor 
antagonists are able to inhibit oedematous responses caused by the various pro-inflammatory agents. 
4.2. Neurogenic Inflammation in the Central Nervous System 
In contrast to classical inflammation the concept of neurogenic inflammation in the brain has until 
very recently remained largely unexplored. Chemical, electrical or immunological stimulation, or 
treatment with capsaicin, was found to elicit a neurogenic inflammatory response in the dura mater but 
not the pia or cerebral cortex [73]. Similarly, intravenous administration of SP to rats has been shown 
to cause a significant increase in plasma extravasation in the dura mater, an effect abolished by  
pre-treatment with an NK1 tachykinin antagonist [74]. It was previously proposed that the activation 
of NK1 tachykinin receptors on vascular endothelium may contribute to cerebral oedema [75]. 
Subsequent studies in a rat diffuse traumatic brain injury (TBI) model have directly confirmed  
a role for SP and neurogenic inflammation in BBB dysfunction and the genesis of vasogenic  
oedema [76–78]. Taken together, these findings indicate that the release of SP may be central to 
changes in BBB permeability following cerebral insults. More recently, the transient receptor potential 
V1 (TRPV1), or the capsaicin receptor, has gained attention as an effector of neuronal injury, largely 
because activation of the TRPV1 receptor initiates neurogenic inflammation. Indeed, there is a high 
degree of localisation of the TRPV1 receptor with SP and CGRP [79] and TRPV1 activation leads to 
an increase in BBB permeability, an effect that is blocked by the TRPV1 antagonist capsazepine [80]. 
Clearly, TRPV1 plays a role in BBB dysfunction in the setting of acute injury to the brain, most likely 
as a facilitator of neurogenic inflammation. 
4.3. Traumatic Brain Injury 
Our group was the first to extend the concept of neurogenic inflammation to the brain in studies of 
TBI, demonstrating that SP release was a ubiquitous feature of acute injury to the brain and was 
associated with marked increases in BBB permeability and the development of vasogenic oedema and 
persistent functional deficits [81]. Specifically, following diffuse TBI in rats, an increase in SP 
immunoreactivity within the injured brain tissue was particularly evident in the perivascular tissue and 
was shown to co-localise with exogenously administered Evan’s Blue (EB), supporting a role for SP in 
increased vascular permeability following trauma [81]. Using the same model, animals chronically 
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pre-treated with capsaicin, an agent shown to deplete of neuropeptides, had significantly reduced BBB 
permeability, cerebral oedema and functional deficits as compared vehicle-treated controls. These 
studies demonstrated that SP release, as part of neurogenic inflammation, was integrally linked to 
increased vascular permeability and cerebral oedema following TBI. Consistent with an important role 
of SP in TBI, clinical and experimental studies have reported adverse effects of ACE [82] or NEP 
inhibition, the enzymes which degrade SP, as this exaggerates the effects of released SP [83]. Indeed, 
ACE and NEP inhibitors have been found to increase plasma extravasation [74]. 
Apart from reports from our own research group [76–78,81,84–90], the study of neuropeptides  
in acute nervous system injury has been mainly confined to isolated reports in peripheral nerve  
injury [91], spinal cord injury [92] and brain ischaemia [75,93,94]. In contrast, neuropeptides have 
been extensively studied in the peripheral nervous system, as well as in asthma, dental pain and 
osteoarthritis [26]. 
4.4. Cerebral Ischemia 
To date, few groups have investigated the role of SP in cerebral ischaemia [75,93,94], and apart 
from our own recent studies, none have characterised the role of neurogenic inflammation. Early 
studies reported that hypoxia of the rat carotid body increased SP release as a function of the severity 
of the hypoxic insult [95]. This finding suggested that SP release may be a tissue response to 
hypoxia/ischaemia. Consistent with this, capsaicin pre- or post-treatment was shown to confer 
protection from neonatal hypoxia-ischaemia injury with a reduction in infarct volume and apoptosis, in 
addition to improved vascular dynamics [96]. Moreover, capsazepine conferred protection from 
increases in microvascular permeability following cerebral ischaemia [97], suggesting that the TRPVI 
receptor was integral to this response. TRPV1 activation was subsequently shown to be involved in 
increased BBB and blood-spinal cord barrier permeability in the setting of peripheral nerve injury [98]. 
In clinical ischaemia, increased SP has been previously reported in the serum of patients with complete 
stroke and TIA [93].  
Our own rat studies have recently shown increased SP immunoreactivity within penumbral tissue at 
24 h following stroke, being particularly marked in perivascular tissue (Figure 2). Such an increase in 
SP was confirmed through SP ELISA of the ischaemic hemisphere [87]. These findings were 
consistent with the increased SP levels previously reported in other central nervous system (CNS) 
disorders such as depression [99] and both experimental and clinical TBI [81,100]. The increase in SP 
was associated with marked disruption to the BBB, as evidenced by increased EB extravasation into 
the brain parenchyma at 24 h post-stroke, thus supporting previous observations of a delayed opening 
of the BBB [101]. At 24 h following 2 h middle cerebral artery occlusion with reperfusion, the 
increased BBB permeability was observed in the setting of profound cerebral oedema, suggesting that 
the oedema had a vasogenic component [87]. Furthermore, profound and persistent functional deficits 
with respect to motor, sensory and neurological function were observed [87].  
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Figure 2. Increased SP immunreactivity was observed at 24 h following acute  
ischaemic stroke (A), as compared to shams (B). This was particularly prominent in the  
perivascular tissue. 
A B 
5. NK1 Tachykinin Receptor Antagonists 
Many groups have hypothesised that antagonists of tachykinin receptors may have several 
therapeutic applications and some of these have been tested in the settings of dental pain, neuropathic 
pain and migraine [26]. The antagonists have also been tested in a model of myocardial 
ischaemia/reperfusion combined with magnesium deficiency, where neurogenic inflammation was 
found to be an early event that initiated inflammatory and pro-oxidative processes that predispose the 
myocardium to reperfusion injury [102]. Inhibiting the SP-induced inflammation and pro-oxidative 
events with an NK1 tachykinin receptor antagonist (L-703, 606) reduced oxidative injury and 
improved functional recovery.  
With respect to neurogenic inflammation, despite the potential utility of NK1 tachykinin receptor 
antagonists to reduce cerebral oedema, until recently only one group investigated the efficacy of NK1 
tachykinin receptor antagonists following cerebral ischaemia [94]. This group reported  
over-expression of SP in conditions of cerebral ischaemia and speculated that SP may play a role in 
exacerbating ischaemic damage. They subsequently administered the NK1 tachykinin receptor 
antagonist SR140333 before the induction of stroke (i.c.v) and found that it significantly reduced 
infarct volume and improved neurological function as measured 24 h after focal cerebral ischaemia. 
Notably the antagonist was administered before injury induction and despite the positive findings, 
there has been no further work published in this area until our own recent studies. We sought to more 
thoroughly characterise the effects of NK1 tachykinin receptor inhibition following acute ischaemic 
stroke. In our studies (Figure 3) employing the rat thread model of stroke, we reported a significant 
improvement in BBB integrity and a reduction in cerebral oedema following treatment with an NK1 
tachykinin receptor antagonist at 4 h post-stroke onset [87]. Animals administered with the NK1 
tachykinin receptor antagonist also demonstrated a marked recovery of functional outcome with 
greatly improved motor, sensory and neurological function over the 7 days post-stroke assessment 
period. Furthermore, the NK1 tachykinin receptor antagonist was able to reduce mortality and the 
incidence of intracerebral haemorrhage following combined treatment with tissue plasminogen 
activator [88]. Taken together with our previous studies in TBI [77,81], these findings suggest that 
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neurogenic inflammation is a feature of acute brain injury and is associated with alterations in 
microvascular permeability and the development of vasogenic oedema. Interventions that block or 
inhibit such neurogenic inflammation are beneficial to outcome, even when administered several hours 
after the acute event. 
Figure 3. Marked BBB permeability, as measured by Evan’s Blue (EB) extravasation (A) 
and cerebral oedema, as measured by the wet weight-dry weight method (B) were observed 
at 24 h following stroke. This was ameliorated by treatment with an NK1 tachykinin 
receptor antagonist. *** p < 0.001 compared to vehicle; + p < 0.05 compared to sham. 
A B 
6. Classical Inflammation 
The role of SP in classical inflammation has been extensively studied. It is well known that SP 
plays a role in the initiation and modulation of a number of inflammatory responses including 
leukocyte activation, endothelial cell adhesion molecule expression, cytokine production and mast cell 
activation amongsy many others [103] and all of these effects are mediated by the NK1 tachykinin 
receptor [104]. Moreover, blocking SP binding at the NK1 tachykinin receptor may attenuate 
inflammatory processes that are SP-mediated. For example, several studies have confirmed that 
astrocytes become “reactive” in response to SP following acute injury, inducing mitogenesis and the 
production of several soluble mediators, such as cytokines, prostaglandins and thromboxane 
derivatives [105,106]. Receptor binding sites for SP have been shown to increase on glia after neuronal 
injury, suggesting a potential role in the glial response to TBI. SP and the NK1 tachykinin receptor are 
also widely expressed by inflammatory cells, including neutrophils, monocytes, eosinophils, dendritic 
cells and activated T cells [23,28,107] suggesting a role in neuroimmunomodulation. Indeed, SP has 
pleiotropic actions in inflammation, with the capacity to stimulate the degranulation of mast cells, and 
stimulate cytokine release including that of interleukin (IL)-1β, tumour necrosis factor (TNF)-α [108] 
and IL-6 [71,109]. Furthermore, SP can modulate the chemotaxis of monocytes [110] and  
neutrophils [111], along with their aggregation, superoxide production [23], adherence to endothelium, 
lysosomal enzyme release and phagocytic activity by neutrophils [112,113]. In turn, the cytokines Il-1β, 
TNF-α and interferon (IFN)-γ can stimulate the release of SP by brain endothelial cells, further 
potentiating the inflammatory response. High levels of SP are found on the surface of rat brain 
endothelial cell cultures following cytokine stimulation [114]. Furthermore, the NK1 tachykinin 
receptor antagonist Spantide was shown to reduce permeability increases induced by IFN-γ and  
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TNF-α, whilst also decreasing the expression of intercellular adhesion molecule-1 (ICAM-1) [115]. 
Such findings suggest that SP plays a major role in the regulation of cytokine-induced BBB damage 
during inflammatory processes in the CNS [114].  
At the level of the endothelium SP is also involved in the expression of adhesion molecules. In a 
study of experimental autoimmune encephalomyelitis treatment with the NK1 tachykinin receptor 
antagonist CP-96,345 was associated with a decline in disease signs in addition to a marked reduction 
in the expression of the adhesion molecules ICAM-1 and vascular cell adhesion molecule-1 on the 
CNS endothelium [116]. Such data suggests that NK1 tachykinin receptor antagonists act to stabilize 
the BBB. SP also induces endothelial cells to produce nitric oxide (NO) [117], which has been 
implicated as an injury factor in stroke, as well as priming polymorphonuclear cells for oxidative 
metabolism (superoxide production) [118], thus providing a source of reactive oxygen species. NK1 
tachykinin receptor antagonists have been shown to reduce pre-necrotic perivascular inflammatory 
infiltration, as well as circulating histamine, prostaglandin E2 and lipid peroxidation products [102]. 
Furthermore, SP binding to its NK1 tachykinin receptor in the CNS has been shown to directly induce 
a non-apoptotic form of programmed cell death in hippocampal, striatal and cortical neurons that is 
independent of caspase activation, but still requiring gene expression [119]. 
The relationship between SP and mast cells in the setting of ischaemic stroke is particularly 
important. Mast cells release nerve growth factor which stimulates a rapid and large release of SP and 
CGRP. SP and mast cells act in a positive feedback loop whereby SP is able to significantly increase 
the number and activation of mast cells. Indeed, aside from their utility in blocking the deleterious 
effects of SP in the acute phase of injury following ischaemic stroke, NK1 tachykinin receptor 
antagonists may also have a utility in the pathogenesis of stroke. A number of studies have now 
detailed a role for SP in thrombosis and atherosclerosis, specifically in the regulation of platelet 
function [120]. Specifically, SP has been shown to influence platelet function by acting as a secondary 
platelet agonist [121]. Administration of the NK1 tachykinin receptor antagonist L733-660 was shown 
to reduce thrombus generation in vitro under arterial flow condition, increase bleeding time in mice 
and provide protection against thromboembolism [122]. Furthermore, SP has been shown to induce 
plaque destabilisation [123]. Through mast cell activation, SP promotes mast cell-dependent  
intra-plaque haemorrhage, [123]. These findings suggest that SP promotes mast cell-dependent plaque 
destabilisation and provides a direct link between tachykinins and vascular inflammation. This may be 
particularly important when considering stroke pathophysiology. Both of these actions were prevented 
with treatment with the NK1 tachykinin receptor antagonist Spantide. NK1 tachykinin receptor 
antagonists may therefore offer an alternative to current anti-thrombotic agents, with a better safety 
profile [120,121]. 
7. Conclusions 
Neurogenic inflammation has long been known to cause plasma extravasation and swelling in 
peripheral tissues. Only recently has the concept of neurogenic inflammation been extended to the 
brain with studies of stroke and traumatic brain injury demonstrating that perivascular SP is increased 
following acute injury to the brain and that it is associated with marked disruption to the BBB and the 
development of vasogenic oedema. Subsequent intervention studies have documented the efficacy of 
NK1 tachykinin receptor antagonists in ameliorating such adverse events. Therefore, modulation of 
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neurogenic inflammation through inhibition of the SP pathway using NK1 tachykinin receptor 
antagonists may provide a novel approach to the management of cerebral oedema following stroke and 
other forms of acute brain injury. 
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